



**PRESS RELEASE**  
FOR IMMEDIATE RELEASE

Contact:

Peter M. DeComo

Chairman & CEO

Renal Solutions, Inc.

(724) 779-7952

[pete.decomo@renalsolutionsinc.com](mailto:pete.decomo@renalsolutionsinc.com)

**RENAL SOLUTIONS COMPLETES \$ 14.7 MILLION SERIES A FINANCING FOR  
DEVELOPMENT OF THE ALLIENT™ SORBENT HEMODIALYSIS SYSTEM**

**PITTSBURGH, PA, December 2, 2002** – Renal Solutions, Inc., the leading provider of sorbent hemodialysis products and services, announced today that it has raised \$14.7 million in private equity capital to accelerate development of the Allient™ sorbent hemodialysis system. This round of financing was led by Birchmere Ventures, with the investor syndicate including Blue Chip Ventures, Draper Triangle Ventures, University of Pittsburgh Medical Center (UPMC), Amkey Ventures and other private individuals and institutions.

The Allient™ is Renal Solutions' lead product and is based on a patent-pending sorbent hemodialysis regeneration system that is being developed by the company. The Allient™ is a self-contained hemodialysis unit utilizing sorbent technology and an innovative and proprietary blood movement system, which together provide for significantly improved safety and ease of use features. The Allient™ addresses many of the limitations of current dialysis products and methods.

“The successful completion of this financing round positions us to finalize development and complete the FDA regulatory process. In addition, we will further establish our infrastructure and prepare for introduction of our products,” said Peter M. DeComo, Chairman and CEO of Renal Solutions, Inc. “We are pleased with this level of interest by our investors and the confidence they have placed in our products and our management team.” “We chose to relocate the Company and establish our Corporate Headquarters and National Distribution Facility in Pittsburgh Pennsylvania because of the significant initiative by the Pittsburgh LifeSciences Greenhouse, including the University of Pittsburgh and Carnegie Mellon University, to foster growth of Life Sciences in the region.” “This initiative coupled with the strong investor support will be key to the success of Renal Solutions as we move forward.”

Gary Glausser, a Partner with Birchmere Ventures who joins Renal Solutions Board of Directors stated that the “new investors are excited about this opportunity as Renal Solutions revolutionary products and services will stimulate a paradigm shift that improves patients health, quality of life and reduces the total cost of health care.”

Renal Solutions, Inc. is the only provider of dialysis products and services utilizing sorbent-based technology to regenerate dialysate. Renal Solutions is a privately held company focused on providing revolutionary products and services for renal failure patients that improve quality of life and aide in the reduction of the total cost of treatment. The Allient™ system is not yet FDA cleared for sale.

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events which could cause results to differ include, failure to meet on-going developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement, for the companies products/services and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward-looking statements.

-END-